<div id="readability-page-1"><p>Prudential PLC increased its holdings in shares of  Pfizer Inc. (NYSE:PFE - Free Report) by 34.4% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor  owned 790,927 shares of the biopharmaceutical company's stock after purchasing an additional 202,251 shares during the quarter. Prudential PLC's holdings in Pfizer were worth $19,172,000 as of its most recent filing with the SEC.</p><ul><li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li></ul><p>Several other institutional investors and hedge funds also recently modified their holdings of PFE. GKV Capital Management Co. Inc. purchased a new position in shares of  Pfizer in the first quarter valued at $27,000.  Curio Wealth LLC boosted its position in  Pfizer by 36,600.0% in the 2nd quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 1,098 shares during the last quarter.  Bayforest Capital Ltd acquired a new stake in shares of  Pfizer during the first quarter valued at about $28,000.  Harbor Asset Planning Inc. purchased a new stake in shares of  Pfizer during the second quarter worth about $29,000.  Finally, WPG Advisers LLC purchased a new stake in shares of  Pfizer during the first quarter worth about $35,000. Hedge funds and other institutional investors own  68.36% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><p>PFE has been the topic of a number of recent analyst reports. Scotiabank assumed coverage on Pfizer in a research report on Thursday, November 13th. They issued a &#34;sector outperform&#34; rating and a $30.00 target price on the stock. Sanford C. Bernstein  restated a &#34;market perform&#34; rating and issued a $30.00 price target on shares of Pfizer in a research note on Friday, October 31st. UBS Group  reaffirmed a &#34;neutral&#34; rating and issued a $28.00 price target on shares of Pfizer in a report on Wednesday, October 1st. Citigroup raised their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a &#34;neutral&#34; rating in a report on Wednesday, August 6th. Finally, Bank of America boosted their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock a &#34;neutral&#34; rating in a research report on Friday, October 3rd. Two research analysts have rated the stock with a Strong Buy rating, four have issued  a Buy rating, twelve have given a Hold rating and one  has given a Sell rating to the company's stock. Based on data from MarketBeat, Pfizer  has a consensus rating of &#34;Hold&#34; and a consensus target price of $28.28.</p><ul><li>Why GRAIL Stock Could Be Biotech’s Next Big Breakout</li></ul><p><b>View Our Latest Report on Pfizer</b></p><h2>Pfizer Price Performance</h2><p>PFE opened at $24.93 on Thursday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The company's 50-day moving average price is $24.83 and its 200 day moving average price is $24.47. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.69. The firm has a market cap of $141.74 billion, a price-to-earnings ratio of 13.26, a price-to-earnings-growth ratio of 0.81 and a beta of 0.54. </p><ul><li>Eli Lilly Strikes Deal With Trump: Why Shares Are Up 10% Since</li></ul><p>Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating analysts' consensus estimates of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, sell-side analysts expect that  Pfizer Inc. will post 2.95 earnings per share for the current year. </p><h2>Pfizer Dividend Announcement</h2><p>The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 7th. This represents a $1.72 annualized dividend and a yield of 6.9%. Pfizer's dividend payout ratio (DPR) is currently 100.00%. </p><h2>Pfizer Company Profile</h2> (Free Report)<p>Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Pfizer</li><li>Biggest Stock Losers - Today’s Biggest Percentage Decliners</li><li>Is Tesla Setting Up for a Year-End Rebound—or a Collapse?</li><li>The How And Why of Investing in Oil Stocks</li><li>Applied Materials: Up 40% in 2025 With Room to Run Long-Term</li><li>The Significance of Brokerage Rankings in Stock Selection</li><li>onsemi Places a $6 Billion Bet on Its Own Stock</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Pfizer Right Now?</h2><p>Before you consider Pfizer, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.</p><p>While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

02378

<p>Prudential PLC increased its holdings in Pfizer Inc. by 34.4% in Q2, owning 790,927 shares worth $19.17 million. Several other institutional investors also modified their holdings. Analysts have mixed ratings on Pfizer, with a consensus rating of 'Hold' and a target price of $28.28. Pfizer reported Q3 earnings of $0.87 per share, beating estimates, with revenue of $16.65 billion. The company announced a quarterly dividend of $0.43 per share, yielding 6.9%.</p>

- Prudential PLC increased its holdings in Pfizer Inc. by 34.4%, owning 790,927 shares valued at $19.17 million after purchasing 202,251 shares in Q2.  
- Several institutional investors also modified their positions in Pfizer, with hedge funds owning 68.36% of the company's stock.  
- Pfizer reported an EPS of $0.87 for Q3, exceeding estimates, and announced a quarterly dividend of $0.43, reflecting a 6.9% yield.

Prudential PLC Raises Holdings in Pfizer Inc. $PFE